aibio
Listings ·
PureTech Health PLC files Form 25 to delist its ADSs from Nasdaq
The filing, dated May 11, 2026, relies on the SEC rule for a voluntary withdrawal by the issuer. It covers American Depositary Shares, each representing 10 ordinary shares.
PRTC PureTech Health PLC
PureTech Health (PRTC) news PRTC delisting news
Latest PureTech Health news
- Listings
PureTech to delist ADSs from Nasdaq and keep its primary London listing
PureTech will delist its American Depositary Shares from Nasdaq and keep its London listing. The Form 25 is expected around May 11, 2026, with the last Nasdaq trading day around May 20, and the company plans to deregister with the SEC afterward.
What PureTech Health does
PureTech Health PLC says its pipeline builds on validated biology of known therapeutics, with unique inventive steps intended to improve clinical pharmacology, and that its technology and drug discovery and development expertise give it a competitive advantage. It also advances products through what it calls Founded Entities. Two internal product candidates are named in the competition section. LYT-100 is aimed at idiopathic pulmonary fibrosis, where the text lists three approved drugs: pirfenidone (Esbriet), nintedanib (Ofev) and nerandomilast (Jascayd). LYT-200 targets galectin-9. The text says it seeks to be the first non-targeted therapy approved in relapsed or refractory acute myeloid leukemia, and that it could also compete as an immuno-oncology treatment. The only other galectin-9 candidate the text mentions is FibroGen's FG-3165, which received IND clearance in June 2024 for solid tumors. The company's business overview and revenue information are incorporated by reference from its Annual Report and Accounts 2025.
| Product or program | What it is | Stage |
|---|---|---|
| LYT-100 | Internal candidate in idiopathic pulmonary fibrosis (IPF) | |
| LYT-200 | Galectin-9 targeting candidate for relapsed or refractory AML and immuno-oncology |
PureTech Health annual financials
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $4.8 million | $3.3 million |
| Research and development | $69.5 million | $96.2 million |
| Net income (loss) | $27.8 million | -$66.6 million |
| Cash from operations | -$134.4 million | -$105.9 million |
| Cash and equivalents | $280.6 million | $191.1 million |
Questions about PureTech Health
Was PureTech Health delisted?
Our latest story on this, dated May 11, 2026: "PureTech Health PLC files Form 25 to delist its ADSs from Nasdaq". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of PureTech Health?
PureTech Health PLC trades under the ticker PRTC on LSE.
Where is PureTech Health listed?
PureTech Health PLC is listed on LSE. Our directory also records these other listings: DUS:0VQ; FWB:0VQ; OTC:PRTCY; OTC:PTCHF; SWB:0VQ.
What is the SEC CIK of PureTech Health?
The SEC Central Index Key (CIK) for PureTech Health PLC is 1782999. Its filings are on SEC EDGAR.
How many shares does PureTech Health have outstanding?
241,684,038 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-29.
Which country or territory is PureTech Health listed under?
Our directory records PureTech Health PLC under United States.
What does PureTech Health do?
Our directory classifies PureTech Health PLC as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of PureTech Health?
The ISIN recorded for PureTech Health PLC is GB00BY2Z0H74.
Does aibio.space cover PureTech Health?
aibio.space lists PureTech Health PLC among 2,820 public biotech companies and publishes its news here as stories appear.
Where is PureTech Health incorporated?
SEC records list its state or country of incorporation as X0.
What does PureTech Health develop?
PureTech Health PLC says its pipeline builds on validated biology of known therapeutics, with unique inventive steps intended to improve clinical pharmacology, and that its technology and drug discovery and development expertise give it a competitive advantage. It also advances products through what it calls Founded Entities.
What is LYT-100 from PureTech Health?
LYT-100: Internal candidate in idiopathic pulmonary fibrosis (IPF)
What is LYT-200 from PureTech Health?
LYT-200: Galectin-9 targeting candidate for relapsed or refractory AML and immuno-oncology
What was PureTech Health's revenue last year?
$4.8 million for the fiscal year ended Dec 31, 2024, as reported to the SEC.
Is PureTech Health profitable?
PureTech Health PLC reported net income of $27.8 million for the fiscal year ended Dec 31, 2024, and used $134.4 million of cash in operations, per its annual report to the SEC.
Investor discussion: PureTech Health
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- PureTech Health plc
- CIK
- 1782999
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- PTCHF (OTC), PRTCY (OTC)
- State or country of incorporation
- X0
- Fiscal year ends
- December 31
- Filer category
- Accelerated filer
- Business address
- 6 TIDE STREET, BOSTON, MA, 02210
- Phone
- 617-482-2333
- Shares outstanding
- 241,684,038 as of 2025-12-31 (20-F filed 2026-04-29)
Recent filings
Listing details
- Company
- PureTech Health PLC
- Ticker
- PRTC
- Listing
- LSE
- Country or territory
- United States
- Business scope
- Biotechnology
- ISIN
- GB00BY2Z0H74
- Other listed symbols
- DUS:0VQ; FWB:0VQ; OTC:PRTCY; OTC:PTCHF; SWB:0VQ
- Last quote in directory
- 2026-10-22
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction